

COMMENTS AND RESPONSES

Response to Comment on: Bosi et al. Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA Randomized Trial. *Diabetes Care* 2013;36:2887–2894

We thank Kleefstra et al. (1) for their interest in our study (2). However, we disagree with the assertions regarding the clinical relevance of our findings on the use of self-monitoring of blood glucose (SMBG) in noninsulin-treated type 2 diabetes.

Although the traditional approach to evaluating the efficacy of pharmacological interventions in type 2 diabetes studies is to report between-group differences in HbA_{1c} reductions, this approach may not be appropriate for assessing the impact of “behavior-based” interventions such as structured SMBG. In pharmacological studies, a medication is administered and investigators measure its efficacy in lowering glucose by comparing the reduction in HbA_{1c} values over time in all patients in the intervention and control group (intent-to-treat [ITT] population). Several researchers, erroneously in our opinion, apply this approach also when evaluating the efficacy of SMBG, looking only at what happens when subjects are asked to perform SMBG, without considering whether patients and/or their clinicians actually do so and interpret and use the data to adjust therapy. In essence, they consider only the *performance* of SMBG as the intervention. Conversely, assessing the proportion of patients who truly complied with the study procedures related to use of structured SMBG (per protocol [PP] population) may provide a more accurate metric for evaluating this type of intervention because it reflects the impact of the complete mode of action (testing and interpreting/using the data) of the intervention (3,4).

In fact, in our study the between-group difference in HbA_{1c} reduction over 12 months was greater in the PP population (−0.21% [95% CI −0.331 to −0.089], $P = 0.0007$) than in the ITT population (all randomized patients) (−0.12% [−0.210 to −0.024], $P = 0.013$). Similarly, the between-group proportion of patients achieving clinically significant reductions in HbA_{1c} at study end (e.g., either >0.3%, >0.4%, or >0.5%) was greater in the PP than ITT population.

Additionally, when evaluating the magnitude of HbA_{1c} reductions, the baseline HbA_{1c} values of study subjects must be considered. As has been shown in numerous intervention studies, diabetic patients with low baseline HbA_{1c} values generally achieve significantly smaller HbA_{1c} reductions compared with subjects with higher baseline values (5). Because approximately 57.3% ($n = 587$) of our subjects had a baseline HbA_{1c} of <7.5% (only 7.6% [$n = 78$] had HbA_{1c} values $\geq 8.5\%$), we did not expect large HbA_{1c} reductions. However, even with these low baseline values, significantly more intervention subjects achieved clinically significant HbA_{1c} reductions (>0.3% or >0.5%) than control subjects.

Given that diabetes is primarily a self-managed disease, future studies may consider using metrics in study design and data analyses that allow assessing the actual impact of behavior-based interventions. Furthermore, as suggested by the results of our study, we need to focus on subgroups of patients with noninsulin-treated type 2 diabetes who may benefit more from structured SMBG (e.g., patients with higher baseline HbA_{1c} values) or where structured SMBG may be a safer choice (e.g., patients with lower baseline HbA_{1c} values).

EMANUELE BOSI, MD^{1,2}
MARINA SCAVINI, MD, PHD^{1,2}
ANTONIO CERIELLO, MD³
DOMENICO CUCINOTTA, MD⁴
ANTONIO TIENGO, MD⁵
RAFFAELE MARINO, MD, MBA⁶
ERMINIO BONIZZONI, PHD⁷
FRANCESCO GIORGINO, MD, PHD⁸

ON BEHALF OF THE PRISMA STUDY GROUP

From the ¹Diabetes Research Institute, San Raffaele Hospital and Scientific Institute, Milan, Italy; the ²San Raffaele Vita-Salute University, Milan, Italy; the ³Institut d'Investigacions Biomèdiques August Pi Sunyer and Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas, Barcelona, Spain; the ⁴Department of Internal Medicine, Policlinico Universitario Gaetano Martino, Messina, Italy; the ⁵Department of Clinical and Experimental Medicine, Division of Metabolic

Diseases, University of Padova, Padova, Italy; ⁶Medical Affairs, Roche Diagnostics, Monza, Italy; the ⁷Department of Occupational Health Clinica del Lavoro L. Devoto, Section of Medical Statistics and Biometry G.A. Maccacaro, School of Medicine, University of Milan, Milan, Italy; and the ⁸Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari School of Medicine, Bari, Italy.

Corresponding author: Emanuele Bosi, bosi.emanuele@hsr.it.

DOI: 10.2337/dc13-1683

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

Acknowledgments—The PRISMA study was funded by Roche Diagnostics Diabetes Care. E.Bos. served on the PRISMA Study Advisory Board funded by Roche Diagnostics Diabetes Care and serves on advisory boards for Roche and Abbott. M.S., A.C., D.C., A.T., and F.G. served on the PRISMA Study Advisory Board funded by Roche Diagnostics Diabetes Care. R.M. is an employee of Roche Diagnostics Diabetes Care. E.Bon. served as statistical consultant for Roche Diagnostics Diabetes Care. The medical writing assistance of Christopher G. Parkin, MS (Information and Education Development, CGParkin, Inc., Las Vegas, NV) was supported by Roche Diagnostics Diabetes Care. No other potential conflicts of interest relevant to this article were reported.

References

1. Kleefstra N, Logtenberg SJJ, Bilo HJG. Comment on: Bosi et al. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. *Diabetes Care* 2013;36:2887–2894 (Letter). *Diabetes Care* 2013;36:e217. DOI: 10.2337/dc13-1394
2. Bosi E, Scavini M, Ceriello A, et al.; PRISMA Study Group. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. *Diabetes Care* 2013;36:2887–2894
3. International Diabetes Federation/SMBG International Working Group. IDF guideline on self-monitoring of blood glucose in noninsulin treated type 2 diabetes [Internet]. Available from <http://www.idf.org/guidelines/self-monitoring>. Accessed 30 December 2012
4. Parkin CG, Buskirk A, Hinnen DA, Axel-Schweitzer M. Results that matter: structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes. *Diabetes Res Clin Pract* 2012;97:6–15
5. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. *Diabetes Care* 2006;29:2137–2139